These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15816604)

  • 1. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.
    Aoe K; Hiraki A; Murakami T; Maeda T; Umemori Y; Katayama H; Eda R; Takeyama H
    Anticancer Res; 2005; 25(1B):415-8. PubMed ID: 15816604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers.
    Kitajima H; Takahashi H; Harada K; Kanai A; Inomata S; Taniguchi H; Saikai T; Abe S
    Respirology; 2006 Mar; 11(2):217-20. PubMed ID: 16548909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
    Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N
    Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
    J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
    Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
    Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
    Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
    Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
    J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute gefitinib-induced pneumonitis.
    Ohyanagi F; Ando Y; Nagashima F; Narabayashi M; Sasaki Y
    Int J Clin Oncol; 2004 Oct; 9(5):406-9. PubMed ID: 15549594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
    Tammaro KA; Baldwin PD; Lundberg AS
    J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent gefitinib-induced interstitial lung disease.
    Suzuki M; Asahina H; Konishi J; Yamazaki K; Nishimura M
    Intern Med; 2008; 47(6):533-6. PubMed ID: 18344641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
    Reck M; Gatzemeier U
    Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer.
    Umemura S; Kishino D; Tabata M; Kiura K; Hotta K; Nishii K; Tanimoto Y; Kanehiro A; Notohara K; Ueoka H; Tanimoto M
    Intern Med; 2005 Sep; 44(9):979-82. PubMed ID: 16258216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
    Kudoh S; Kato H; Nishiwaki Y; Fukuoka M; Nakata K; Ichinose Y; Tsuboi M; Yokota S; Nakagawa K; Suga M; ; Jiang H; Itoh Y; Armour A; Watkins C; Higenbottam T; Nyberg F
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1348-57. PubMed ID: 18337594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids.
    Seto T; Seki N; Uematsu K; Tanigaki T; Shioya S; Koboyashi T; Umemura S; Eguchi K
    Respirology; 2006 Jan; 11(1):113-6. PubMed ID: 16423212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
    Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
    Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
    Endo M; Johkoh T; Kimura K; Yamamoto N
    Lung Cancer; 2006 May; 52(2):135-40. PubMed ID: 16574271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.
    Chou CL; Ko HW; Wang CW; Yu CT; Kuo HP; Huang CD
    Chang Gung Med J; 2010; 33(1):100-5. PubMed ID: 20184801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe acute interstitial pnuemonia and gefitinib.
    Sumpter K; Harper-Wynne C; O'Brien M; Congleton J
    Lung Cancer; 2004 Mar; 43(3):367-8. PubMed ID: 15165098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.